Cyclerion Therapeutics (NASDAQ:KRSA) Rating Increased to Strong-Buy at UBS Group

Cyclerion Therapeutics (NASDAQ:KRSA) was upgraded by analysts at UBS Group to a “strong-buy” rating in a report released on Thursday, Zacks reports.

Separately, Zacks Research upgraded Cyclerion Therapeutics to a “hold” rating in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $55.00.

Cyclerion Therapeutics Stock Up 29.9%

KRSA opened at $31.91 on Thursday. Cyclerion Therapeutics has a 12-month low of $7.19 and a 12-month high of $59.36.

Cyclerion Therapeutics Company Profile

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for serious diseases of the central nervous system. The company has concentrated on therapies designed to influence the nitric oxide–soluble guanylate cyclase signaling pathway, which may play a role in neurological and other debilitating conditions.

Cyclerion’s lead development program was IW-6463, an oral, central nervous system-penetrant soluble guanylate cyclase stimulator investigated for potential use in neurodegenerative diseases, including Alzheimer’s disease and amyotrophic lateral sclerosis.